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 INTRODUCTION 
 
1. THE METABOLIC SYNDROME 
 
The metabolic syndrome has received increased attention in the past few years. It consists of 
multiple, interrelated risk factors of metabolic origin that appear to directly promote the 
development of atherosclerotic cardiovascular disease (ASCVD). This constellation of metabolic 
risk factors is strongly associated with type 2 diabetes mellitus or the risk for this condition. The 
metabolic risk factors consist of atherogenic dyslipidemia, elevated blood pressure, elevated plasma 
glucose and visceral obesity. 
Several different sets of criteria have been proposed during the past decade for diagnosis of the 
metabolic syndrome. In 2001, the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel III (ATP III) proposed a simple set of diagnostic criteria based on common clinical 
measures including waist circumference, triglycerides, HDL-C, blood pressure, and fasting glucose 
level ((al.)1). The presence of defined abnormalities in any 3 of these 5 measures constitutes a 
diagnosis of the metabolic syndrome (Table 1). 
The ATP III criteria for the metabolic syndrome have been widely used in both clinical practice and 
epidemiological studies. The criteria also have the advantage of avoiding emphasis on a single 
cause.  
In 2005, the International Diabetes Federation (IDF) has proposed a new classification that includes 
central obesity as an essential element for the diagnosis, changing the parameters of waist 
circumference (Table 1). 
 
 
 
 
 
 
 
 
 
  
Table 1. Diagnostic criteria for metabolic syndrome 
NCEP-ATPIII IDF 
Waist circumference 
• ≥ 102 cm  in men 
• ≥ 88 cm  in women 
Triglycerides ≥ 150 mg/dl or drug treatment 
HDL cholesterol  
• < 40 mg/dl in men 
• < 50 mg/dl in women 
Blood pression 
• ≥ 130 mm Hg systolic  
Or 
• ≥ 85 mm Hg diastolic  
Or drug treatment for hypertension 
Fasting glucose ≥ 100 mg/dl or previous 
diagnosis of type 2 diabetes 
Waist circumference 
• ≥ 94 cm  in men 
• ≥ 80 cm  in women 
Triglycerides ≥ 150 mg/dl or drug treatment 
HDL cholesterol  
• < 40 mg/dl in men 
• < 50 mg/dl in women 
Blood pression 
• ≥ 130 mm Hg systolic  
Or 
• ≥ 85 mm Hg diastolic  
Or drug treatment for hypertension 
Fasting glucose ≥ 100 mg/dl or previous 
diagnosis of type 2 diabetes 
 
Prospective population studies show that the metabolic syndrome confers an  2-fold increase in 
relative risk for ASCVD events, and in individuals without established type 2 diabetes mellitus, an  
5-fold increase in risk for developing diabetes as compared with people without the syndrome. This 
finding implies that the metabolic syndrome imparts a relatively high long-term risk for both 
ASCVD and diabetes (1).  
At present, it is not clear whether the metabolic syndrome has a single cause, and it appears that it 
can be precipitated by multiple underlying risk factors. The most important of these underlying risk 
factors are abdominal obesity and insulin resistance.  
The abdominal visceral adipose tissue is  a source of cytokines and adipokines that influence 
interactions between the immune system and the vascular wall, inducing a state of chronic 
inflammation and increased oxidative stress (2). When the picture is complicated with metabolic 
changes on carbohydrate and lipid metabolism, the risk factors for cardiovascular and 
cerebrovascular disease, already high in a state of uncomplicated obesity, increased. It is still not 
clear what is the alteration of departure, but it seems increasingly clear that the single alteration 
should be able to influence each other defining a complex metabolic condition as that of the 
metabolic syndrome. 
  
 
 
2. LIPOPROTEINS BIOCHEMISTRY 
 
Cholesterol and triacylglycerol are transported in blood as lipoproteins. Lipoproteins are generally 
spherical particles, with a surface layer composed of phospholipid with the fatty acids oriented 
toward the core of the particle. Included in this phospholipid layer are specific proteins known as 
apolipoproteins and free cholesterol. The core of the lipoprotein particles is made up of cholesteryl 
ester and triacylglycerol molecules. 
The classification of serum lipoproteins has evolved historically through several phases 
corresponding with the development of different laboratory methodologies. 
With the arrival of the analytical ultracentrifugation in the 1940s, lipoproteins were classically 
separated into four major classes designated as chylomicrons (exogenous triacylglycerol-rich 
particles of d <0.94 g/ml), very low-density lipoproteins (VLDL, endogenous triacylglycerol- rich 
particles of d=0.94–1.006 g/ml), LDL (cholesteryl ester-rich particles of d=1.006– 1.063 g/ml), and 
HDL (particles containing approximately 50% protein of d=1.063– 1.21 g/ml). With subsequent 
improvements to the ultracentrifugation techniques, further heterogeneity was detected within each 
of those major lipoprotein classes; this resulted in the need for further subdivision into several 
density subclasses such as HDL2a (d=1.10–1.125 gml_1), HDL2b (d=1.063– 1.10 gml_1), and 
HDL3 (d=1.125–1.21 gml_1). There is no doubt that the separation of lipoproteins by 
ultracentrifugation has been essential for the advances in this field. 
 
2.1 SYNTHESIS AND CATABOLISM OF LIPOPROTEINS 
 
2.1.1 Metabolism of Lipoproteins Carrying Exogenous Lipids 
 
Dietary fats absorbed in the intestine are packaged into large, triacylglycerol-rich chylomicrons for 
delivery through the bloodstream to sites of lipid metabolism or storage. These lipoproteins interact 
with lipoprotein lipase (LPL) and undergo lipolysis, forming chylomicron remnants. The major 
sites of LPL activity are adipose tissue, skeletal muscle, the mammary gland, and the myocardium. 
In these sites, the fatty acids from the trcacylglycerols are used for storage, oxidation, or secretion 
back to the circulation. The triacylglycerol-depleted particles resulting from the lipolysis, known as 
chylomicron remnants, pick up apo E and cholesteryl ester from HDL and are rapidly taken up by 
the liver via a process mediated by the apo E receptor. This is a fast process and chylomicron 
particles are not usually present in the blood after a prolonged fasting period. The occurrence of 
chylomicronemia can be easily detected by the presence of a creamy supernatant floating on top of 
the plasma or serum kept several hours at 4 °C. 
 
 
2.1.2 Transport of Endogenous Lipids 
 
The liver cell secretes triacylglycerol-rich VLDL, which can be converted first to intermediate-
density lipoprotein (IDL) and then to LDL through lipolysis by a mechanism similar to that 
described for chylomicrons. The excess surface components are usually transferred to HDL, and the 
triacylglycerol-depleted VLDL becomes an IDL. Some of these particles may be taken up by the 
liver via an apo E receptor, whereas others are further depleted of triacylglycerols, becoming 
cholesteryl ester-enriched particles known as LDL, which contain apo B as their only 
apolipoproteins. Consumption of fat-rich meals or glucose enhances VLDL production. Some 
primary causes of elevated VLDL or IDL levels are familial endogenous hypertriglyceridemia (type 
IV according to Fredrickson’s classification) and familial dysbetalipoproteinemia (type III 
hyperlipidemia). Genetic mutations at the apo E gene locus are responsible for the type III 
phenotype. Some secondary causes for elevated VLDL levels are obesity, diabetes mellitus, alcohol 
consumption, as well as the use of high doses of certain drugs (e.g., thiazide diuretics and 
estrogens). The presence of elevated levels of IDL has been associated with an increased 
atherosclerotic risk. LDL particles are major carriers of cholesteryl ester in the blood. An LDL 
receptor that recognizes apo B-100 and apo E, but not apo B-48, allows the liver and other tissues to 
catabolize LDL. High-fat and high-cholesterol diets can decrease the activity of the LDL receptor, 
leading to increased levels of circulating LDL. These particles supply cholesterol to cells in the 
periphery for synthesis of cell membranes and steroid hormones. Modified or oxidized LDL can 
also be taken up by the scavenger receptor on macrophages in various tissues, including the arterial 
wall. This process is a potential initiator of foam cell formation and atherosclerosis. Several LDL 
subclasses have been identified using gradient gel electrophoresis. Large, less dense LDL particles 
are commonly found in premenopausal women and men at low risk for CHD, whereas the small, 
more dense particles have been associated with a significant increased risk for myocardial 
infarction. The distribution of these particles appears to have a significant genetic component 
modulated by age and environmental factors. 
 
2.1.3 Reverse Cholesterol Transport 
 
HDL is synthesized by both the liver and the intestine. Its precursor form is discoidal in shape and 
matures in circulation as it picks up unesterified cholesterol from cell membranes and other lipids 
(phospholipid and triacylglycerol) and proteins (AI, E, and C apolipoproteins) from 
triacylglycerolrich lipoproteins (chylomicron and VLDL) as these particles undergo lipolysis. The 
cholesterol is esterified by the action of the lecithin–cholesterol acyltransferase (LCAT) and the 
small HDL3 particle becomes a larger HDL2 particle. The esterified cholesterol is either delivered 
to the liver or transferred by the action of cholesteryl ester transfer protein (CETP) to other 
lipoproteins (such as chylomicron, VLDL remnants, or LDL) in exchange for triacylglycerols. This 
cholesterol may then be taken up by the liver via receptors specific for these lipoproteins, or 
it can be delivered again to the peripheral tissues. The triacylglycerol received by HDL2 is 
hydrolyzed by hepatic lipase and the particle is converted back to HDL3, completing the HDL cycle 
in plasma. In the liver, cholesterol can be excreted directly into bile, converted to bile acids, or 
reutilized in lipoprotein production. Several genetic disorders have been identified associated with 
low levels or total deficiency of HDL(4). 
 
 
 
 3. THE ROLE OF OXIDIZED LIPOPROTEINS LDL IN 
ATHEROGENESIS 
 
LDL lipoproteins are composed of a core enriched in hydrophobic triglycerides and cholesterol 
ester molecule, enclosed by an envelope of phospholipids and unesterified cholesterol and 
lipoprotein ApoB 100 (5). 
The lipoproteins LDL are generally divided into three main subclasses based on density: LDL1 and 
LDL2 (density 1018-1030 g / mL), LDL3 (1030-1040 g / mL), LDL4 and LDL5 (1040-1065 g / 
mL). The small, dense LDL can penetrate more easily into the subendothelial space of the vascular 
wall and are more susceptible to oxidation (6). Several components of LDL, including ApoB, 
phospholipids, cholesterol and unsaturated fatty acids may be subject to oxidative stess (7). Vitamin 
E is the principal fat soluble antioxidant that protects lipoproteins, but when it is consumed, the 
chain reaction continues and develops degradation products as the malonilaldeide (MDA) (8). 
Aldehydes can form Schiff bases with amino groups of lysine residues, creating cross-links between 
lipids and proteins or between lipid molecules. These changes alter the protein fraction and reduce 
the affinity of LDL for its receptor, but increases the affinity for the scavenger receptor of 
macrophages, through which oxidized LDL exert their atherogenic action. Macrophages incorporate 
oxidized LDL, contributing to foam cell formation and playing a key role in cellular events that lead 
to the development of atherosclerotic lesions. The oxidation of lipoproteins in the plasma seems to 
occur with difficulty due to the presence of high concentrations of antioxidants and proteins that 
chelate metal (9).  
It has been suggested that oxidized LDL are generated in the vessel wall and spread into the 
bloodstream after plaque rupture, increasing the permeability of plaque and leading to the ischemic 
and inflammatory damage (10). Several studies have found wide variation in susceptibility of LDLs 
from different individuals to oxidation ex vivo,  though it has yet to be demonstrated 
convincingly that such variations are associated with the risk of atherosclerosis (9). Vitamin E, the 
major antioxidant carried in LDL, may be one factor that influences the susceptibility of LDL to 
oxidation. Increasing the vitamin E content of lipoproteins in vitro or in vivo (by dietary 
supplementation) increases the lag phase for initiation of LDL oxidation under certain conditions. 
Other lipoprotein characteristics such as size and density also influence the extent of oxidation. 
Smalldense LDL is more susceptible to oxidation than large buoyant LDL,  and increased levels of 
small-dense LDLs are seen in various conditions that increase the risk of vascular disease, including 
diabetes, combined hyperlipidemia, and familial dyslipidemic hypertension. The increased 
susceptibility to oxidation may relate to these particles’ increased content of triglycerides, 
polyunsaturated fatty acids, and/or decreased vitamin E content. (9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
4. HDL LIPOPROTEIN 
 
The high-density lipoprotein (HDL) have been described for the first time in the early 50's with the 
ultacentrifugation  density gradient method to separate the main classes of lipoproteins. Important 
epidemiological studies, most notably the Framingham Heart Study, have demonstrated a powerful 
inverse relationship between cardiovascular disease and plasma concentrations of HDL cholesterol 
(10). Low levels of HDL cholesterol (<40 mg / dl in women and <50 mg / dl in males) were 
identified as independent risk factors for cardiovascular disease, both in diabetics, both in non-
diabetic subjects (11). 
 
4.1 Functional HDL: structure, composition, and heterogeneity 
 
Functional plasma HDL are spherical or discoidal particles of high hydrated density (1.063-1.21 
g/ml) due to elevated protein content (>30% by weight) compared with other lipoproteins (12;13). 
Discoidal HDL are small particles consisting primarily of apoA-I embedded in a lipid monolayer 
constituted of PL and free cholesterol (14;15). Spherical HDL are larger and additionally contain a 
hydrophobic core formed by cholesteryl esters (CE) and small amounts of TG. ApoA-I (molecular 
mass 28 kDa) is the major structural HDL apolipoprotein and accounts for ∼70% of total HDL 
protein, whereas the second major HDL apolipoprotein, apoA-II, represents ∼20%. Minor HDL 
protein components (typically <10% of the HDL protein moiety) include apoE, apoA-IV, apoA-V, 
apoJ, apoC-I, apoC-II, and apoC-III (13). In small discoidal HDL, two molecules of apoA-I adopt a 
“double belt” orientation with their helixes oriented parallel to the plane of the disc and 
perpendicular to the lipid acyl chains in such a way that they wrap around the lipid bilayer disc 
forming two stacked rings in an antiparallel orientation (17); furthermore, apoA-I molecules appear 
to slide in relation to each other between two stable conformations (18). Plasma HDL particles also 
carry enzymes involved in lipid metabolism, including lecithin/cholesterol acyltransferase (LCAT), 
enzymes with plausible antioxidative activities, such as platelet-activating factor-acetyl hydrolase 
(PAF-AH, also called lipoprotein-associated phospholipase A2), paraoxonase 1 (PON1) and 
glutathione selenoperoxidase (GSPx), and other proteins and peptides, such as serum amyloid A 
(SAA), a major positive acute-phase reactant, α-1-antitrypsin, or amyloid-β, the principal 
constituent of senile plaques in Alzheimer's disease (17).  
 Heterogeneity in the physicochemical properties of normal functional HDL in healthy 
normolipidemic subjects (18).  
Plasma HDL particles are highly heterogeneous in their physicochemical properties, metabolism, 
and biological activity (13). Such heterogeneity results from differences in relative contents of 
apolipoproteins and lipids in HDL and is intimately related to the amphipathic helical structure of 
human apoA-I (19); these helixes possess a hinge domain that allows apoA-I to switch between two 
conformations corresponding to HDL particles of different size. When fractionated by 
ultracentrifugation, human HDL is typically separated into two major subfractions, HDL2 (d 1.063-
1.125 g/ml) and HDL3 (d 1.125-1.21 g/ml) (20). Given the complexity of HDL particle 
heterogeneity, small, dense HDL will be defined for present purposes as lipid-poor and protein-rich 
discoidal and spherical HDL particles of small size (≤9 nm), low molecular mass (≤200 kDa), and 
high density (1.125-1.24 g/ml). Depending on the fractionation method, small, dense HDL may 
include HDL3a, 3b, and 3c and very high-density lipoprotein separated by ultracentrifugation and 
pre-β-HDL separated by gradient gel electrophoresis.  
The clinical relevance of circulating levels of individual HDL subfractions to atherosclerosis and 
CV disease is, however, unclear Furthermore, plasma levels of either large (21) or small (22) HDL 
were reported to be associated with the progression of coronary atherosclerosis.  
 
4.2 Metabolism 
 
Spherical plasma HDL are mature particles generated by intravascular processes from lipid-free 
apoA-I or lipid-poor pre-β-HDL (Fig. 1) (23). These small HDL precursors are produced as nascent 
HDL by the liver or intestine, are also released as surface fragments from lipolysed TG-rich 
lipoproteins (VLDL and chylomicrons), and finally may be generated during the interconversion of 
HDL3 and HDL2. Small nascent HDL are unstable and readily acquire lipids (24); their initial 
lipidation occurs at cellular membranes via the ATP-binding cassette transporter (ABC) A1-
mediated efflux of cholesterol and PL from cells (25). ABCA1 is a major player in HDL 
metabolism; indeed, genetic defects in ABCA1 as occur in Tangier disease may result in low HDL-
C levels, with cholesterol accumulation in peripheral tissues and premature atherosclerosis (25).  
 
  
Fig. 1.  
Intravascular HDL particle remodeling and metabolism in normolipidemia. Spherical plasma HDL are generated from lipid-free apoA-I or lipid-poor 
pre-β-HDL, which are produced as nascent HDL by the liver or intestine but can also be released as surface fragments from lipolysed TG-rich 
lipoproteins and/or during the interconversion of HDL3 and HDL2. Initial lipidation of small nascent HDL occurs at cellular membranes via the 
ABCA1-mediated efflux of cholesterol and PL from cells. Subsequent LCAT-mediated cholesterol esterification generates large spherical HDL2 
particles, which undergo further remodeling via particle fusion and surface remnant transfer mediated by PLTP. Large HDL2 can be converted in turn 
to small HDL3 upon CETP-mediated transfer of CE from HDL to apoB-containing lipoproteins, upon SR-BI-mediated selective uptake of CE by the 
liver and steroidogenic organs, and HL- and endothelial lipase-mediated hydrolysis of TG. When CETP-mediated transfer of CE occurs between HDL 
and TG-rich lipoproteins, TG-rich HDL are generated, which can be further hydrolyzed by HL to small, TG-rich HDL particles. The concerted action 
of CETP and HL promotes reduction in HDL size, formation of lipid-poor HDL particles, and shedding from HDL of lipid-free apoA-I, which can 
interact with ABCA1 in the next lipidation cycle. HDL lipids are catabolized either separately from HDL proteins by selective uptake or via CETP 
transfer or as holoparticles together with HDL proteins primarily in the liver via uptake through LDL receptors for apoE-containing HDL and through 
hitherto unidentified receptors for HDL holoparticles. EL, endothelial lipase; FC, free cholesterol; HDL-R, HDL holoparticle receptor; LDL-R, LDL 
receptor.  
 
 
Subsequent LCAT-mediated esterification of cell-derived cholesterol generates large spherical HDL 
particles with a neutral lipid core of CE and TG ; such particles undergo further remodeling via 
particle fusion and surface remnant transfer mediated by phospholipid transfer protein (PLTP). 
Large HDL2 can be converted in turn to small HDL3 upon cholesteryl ester transfer protein 
(CETP)-mediated transfer of CE from HDL to apoB-containing lipoproteins, upon scavenger 
receptor type BI (SR-BI)-mediated selective uptake of CE by the liver and steroidogenic organs and 
hepatic lipase (HL) and upon endothelial lipase-mediated hydrolysis of core TG (26). When CETP-
mediated transfer of CE occurs between HDL and TG-rich lipoproteins, TG-rich HDL are 
generated, which can be further hydrolyzed by HL to small, TG-rich HDL particles (27). The 
concerted action of CETP and HL promotes reduction in HDL size, formation of lipid-poor HDL 
particles and shedding from HDL of lipid-free apoA-I, which can interact with ABCA1 in the next 
lipidation cycle (28). HDL lipids are catabolized either separately from HDL proteins by selective 
uptake or via CETP transfer or as holoparticles primarily in the liver, via uptake through LDL 
receptors for apoE-containing HDL and through hitherto unidentified receptors for HDL 
holoparticles.  
 
4.3 Biological Activities 
 
HDL particles possess multiple antiatherogenic. The central role of HDL in cellular cholesterol 
efflux and RCT is considered to form a basis for the capacity of HDL to attenuate atherogenesis. 
However, compelling evidence has emerged that additional dimensions of the antiatherogenic 
action of HDL may be of major physiological and pathological relevance (29).  
 
4.3.1  Cholesterol Efflux Capacity 
 
The cholesterol efflux capacity of HDL particles is related to their ability to remove cholesterol 
from membranes of peripheral cells and particularly macrophages and foam cells via interaction 
with the ABCA1 and ABCG1 transporters and/or SR-BI receptor. Apolipoprotein-mediated lipid 
efflux involves specific interactions with membrane proteins, desorption of membrane lipids from 
caveolae, lipidation of lipid-free apolipoproteins and production of small, lipid-poor HDL (26). 
Lipid-free apolipoproteins remove cholesterol and PL from macrophages, aortic smooth muscle 
cells, and normal human skin fibroblasts but not from fibroblasts of patients with Tangier disease 
(25). Defective ABCA1 transporter function in Tangier disease has provided clear evidence that 
ABCA1 has a central role in lipid efflux mediated by lipid-poor apolipoproteins. In support of this 
mechanism, apoA-I-mediated cholesterol efflux is severely decreased by inhibition of ABCA1 with 
either antisense oligonucleotides or pharmacological compounds but is increased by the 
overexpression of ABCA1 (25). Thus, ABCA1 is a pivotal regulator of cellular cholesterol efflux 
and of the lipidation of apoA-I, a key step in formation of mature, spherical HDL particles.  
ABCA1 has two highly conserved cytoplasmic ATP binding cassettes and two transmembrane 
domains, each of which consists of six membrane-spanning segments (30). It has been suggested 
that ABCA1 forms a channel within the plasma membrane through which cholesterol and PL are 
transferred (“flopped”) from the inner to the outer leaflet of the plasma bilayer membrane et al. 
There the lipids may be picked up by lipid-free apolipoproteins or lipid-poor particles, which bind 
to ABCA1 (31).  
In addition to ABCA1, there are several other sterol-regulated ABC transporters, including ABCG1 
and ABCG4, which are involved in cholesterol efflux from macrophages to mature HDL2 and 
HDL3 particles (32). The relative quantitative importance of cholesterol efflux mediated by 
ABCA1 compared with ABCG1 in macrophages remains unclear.  
In contrast to lipid-free apolipoproteins, lipid-containing HDL particles induce both specific and 
nonspecific forms of cholesterol efflux (26). Nonspecific cholesterol efflux can be also mediated by 
PL vesicles, synthetic cyclodextrins, albumin or partially proteolysed HDL; it is slow, unsaturable, 
and bidirectional and thus appears to occur by aqueous diffusion . It has been suggested that SR-BI 
mediates the bidirectional flux between mature HDL and plasma membranes through the binding of 
HDL particles and subsequent reorganization of lipids within cholesterol- and caveolae-rich 
domains in the plasma membrane . The PL content of HDL is an important determinant of such SR-
BI-mediated cholesterol efflux (33).  Finally, HDL-mediated cholesterol efflux from macrophages 
may be facilitated by apoE secretion (34). Indeed, macrophage-derived apoE can associate with 
HDL and improve its cholesterol acceptor properties.  
Distinct cholesterol efflux properties of lipid-free and lipid-containing HDL are indicative of 
functional heterogeneity of HDL particles. Indeed, a decrease in the lipid content of HDL is 
generally thought to increase its capacity to remove cellular cholesterol; small, dense, lipid-poor, 
protein-rich HDL particles are therefore considered to represent more efficient cholesterol acceptors 
compared with their large, light, lipid-rich, protein-poor counterparts (26), thereby same authors 
suggest that lipid-free, rather than lipid-poor, apolipoproteins function as primary cholesterol 
acceptors (37). Lipid-free and/or lipid-poor HDL apolipoproteins induce cholesterol uptake via 
interaction with ABCA1; conversely, large, lipid-rich HDL particles appear to represent a better 
ligand for cellular uptake of CE mediated by SR-BI compared with small, lipid-poor, consistent 
with the role of these particles in RCT from peripheral cells to the liver (26,37).  
 
 
4.3.2  Antioxidative Activity 
 
HDL antioxidative activity is typically observed as inhibition of LDL oxidation by HDL; LDL is 
thought to represent the major physiological target of HDL antioxidative action in vivo (29). HDL 
is also able to inhibit generation of reactive oxygen species (ROS) in vitro under conditions of cell 
culture and in vivo in a rabbit model of acute arterial inflammation . In addition, inhibitory actions 
of HDL on LDL oxidation have been reported in vitro upon their coincubation and in vivo upon 
HDL injection. HDL potently protects both lipid and protein moieties of LDL and inhibits 
accumulation of various oxidation products in LDL, including oxidized PL and short-chain 
aldehydes (36,29).  
The antioxidative activity of HDL is related to the presence of several apolipoproteins and enzymes 
with antioxidative properties in HDL particles. Apolipoproteins that possess antioxidative activity 
include apoA-I, apoE, apoJ, apoA-II, and apoA-IV. It appears that a major component of the 
antioxidative activity of HDL can be ascribed to apoA-I which can prevent and/or delay LDL 
oxidation by removing oxidized PL, including 1-palmitoyl-2(5-oxovaleroyl)-sn-glycero-3-
phosphorylcholine and 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine, from LDL and 
from arterial wall cells (37). The capacity of apoA-I to remove oxidized lipids is not specific for 
arterial wall cells, because similar effects have been reported for erythrocytes (36). Circulating 
HDL accumulate LOOH and have been proposed to function as a “sink” for oxidized lipids (39), 
ensuring their efficient elimination from the circulation through the liver.  
ApoE possesses established antiatherosclerotic activity, which is normally ascribed to its lipid 
transport properties . However, the action of apoE goes beyond such activity. Indeed, apoE 
possesses distinct antioxidative properties and can promote regression of atherosclerosis 
independently of lowering plasma cholesterol levels (40). HDL-associated apoJ can inhibit 
oxidation of LDL by artery wall cells ; in addition, apoJ is cytoprotective at low physiological 
levels. The beneficial actions of apoJ may be related to its ability to maintain integrity of membrane 
and lipoprotein lipids via its hydrophobic-binding domains (29). Antioxidative properties have also 
been reported for apoA-II  and apoA-IV. The capacity of apoA-II to protect LDL from oxidation is, 
however, questionable, given the fact that overexpression of human apoA-II in dyslipidemic mice 
accelerates atherosclerosis, increases aortic accumulation of oxLDL, and reduces antioxidative 
activity of HDL. Such proatherogenic actions of apoA-II may be related to the displacement of 
antiatherogenic apoA-I and PON1 by apoA-II from HDL particles (41). Finally, HDL is able to 
function as a preventive antioxidant through its capacity to bind transition metal ions, which in free 
form are potent catalyzers of LDL oxidation. Intriguingly, plasma HDL carry amyloid-β peptide, a 
major component of senile neuritic plaques and a strong chelator of transition metals (29).  
Major HDL enzymes possessing antioxidative activity are PON1, PAF-AH, LCAT, and GSPx (29). 
PON1 is a component of HDL that is thought to hydrolyze LDL-derived short-chain oxidized PL 
once they are formed (42). PON1 is anchored to lipids via its hydrophobic N terminus; the 
association of PON1 with HDL is a prerequisite for maintaining normal serum activity of the 
enzyme. HDL provides the optimal physiological acceptor complex for PON1, in terms of both 
stimulating enzyme secretion and stabilizing the secreted peptide ; PON1 interaction with apoA-I is 
critical for enzyme stability . HDL and, less efficiently, VLDL but not LDL promote PON1 
secretion from cells; the differences between these lipoproteins are related to differences in their 
lipid composition (43).  
PAF-AH and LCAT can also hydrolyze LDL-derived short-chain oxidized PL; the relationship 
between the hydrolyzing activities of PON1, PAF-AH, and LCAT toward oxidized PL remains 
unclear. Recent data question the ability of PON1 to hydrolyze oxidized PL and suggest that PAF-
AH, rather than PON-1, is the oxidized PL hydrolase in HDL. Consistent with this conclusion, 
HDL-associated PAF-AH is thought to play an antiatherogenic role, in contrast to the LDL-
associated. Indeed, local arterial expression of PAF-AH reduces accumulation of oxLDL and 
inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured 
carotid arteries of nonhyperlipidemic rabbits (44).  
The antioxidative activity of PON1 purified from human serum has recently been ascribed to the 
presence of detergents or some other unidentified proteins. Interestingly, PON1 has been reported to 
catalyze the hydrolysis of a variety of lactones, including homocysteine thiolactone, suggesting that 
its native activity is as a lactonase. Plasma levels of homocysteine are a strong CV risk factor; by 
detoxifying homocysteine thiolactone, PON1 could protect against homocysteinylation, a post-
translational modification of proteins associated with attenuated biological activity and a potential 
contributing factor to atherosclerosis (38).  
In addition, HDL-associated PON1 enhances cholesterol efflux from macrophages via increased 
HDL binding mediated by ABCA1 PON1-induced cellular accumulation of 
lysophosphatidylcholine, which stimulates cholesterol efflux via the ABCA1 pathway, may account 
for this effect. One can hypothesize that both lactonase activity and an RCT-related mechanism may 
contribute to the antiatherosclerotic effects of PON1 observed in vivo (45).  
Another HDL enzyme, GSPx, can reduce LOOH to corresponding hydroxides and thereby detoxify 
them. LOOH-reducing activity mediated by Met residues of apoA-I and apoA-II has also been 
reported. Finally, upon HDL oxidation with peroxynitrite, apoA-I increases generation of PL core 
aldehydes that are subsequently hydrolyzed by HDL-associated enzymes, such as PAF-AH and/or 
PON1, with formation of lysophospholipids. Such a PAF-AH/PON1-coupled protective function of 
apoA-I can effectively divert proatherogenic LOOH to less harmful products (36; 29).  
Apolipoproteins and enzymes with antioxidative activities are nonuniformly distributed across HDL 
subfractions. In vivo PON1 is preferentially associated with large HDL but can be displaced to 
small, dense particles upon ultracentrifugation (15,16). The size and shape of HDL seem to be 
critical for PON1 binding (38). By contrast, apoJ is associated with a subset of small HDL, which 
also contains PON1 (41). Similarly, LCAT activity (18), PAF-AH activity (18), and apoA-IV (41) 
are enriched in small, dense HDL isolated by ultracentrifugation. As a consequence, HDL particles 
are heterogeneous in their antioxidative activity. Under mild oxidative stress induced by an azo 
initiator 2,2′-azobis-(2-amidinopropane) hydrochloride or Cu2+, the antioxidative activity of HDL 
subfractions isolated by density gradient ultracentrifugation against LDL oxidation increases with 
increment in density in the order: HDL2b < HDL2a < HDL3a < HDL3b < HDL3c, thereby 
establishing that small, dense HDL act as potent protectors of LDL from oxidative stress. Similarly, 
HDL3 is a more potent protector of LDL from in vitro oxidation compared with HDL2. The 
antioxidative activity of small, dense HDL is related to the inactivation of proatherogenic products 
of LDL lipid peroxidation, primarily LOOH. Mechanistically, this activity may arise from synergy 
in inactivation of oxidized lipids by enzymatic (hydrolysis) and nonenzymatic (physical removal) 
mechanisms, in part reflecting distinct intrinsic physicochemical properties of the small, dense 
HDL3c subfraction (15).  
The relative importance of HDL antioxidative activity in the overall cardioprotective effect of HDL 
compared with other biological actions remains indeterminate. 
 
4.3.3  Anti-Inflammatory Activity 
 
The anti-inflammatory activity of HDL is illustrated by the ability of HDL to decrease cytokine-
induced expression of adhesion molecules on endothelial cells and to inhibit monocyte adhesion to 
these cells. HDL efficiently inhibit expression of the vascular cell adhesion molecule-1, intercellular 
adhesion molecule-1, and E-selectin in vitro induced by tumor necrosis factor-α (TNF-α), 
interleukin (IL)-1, or endotoxin. Moreover, this potent anti-inflammatory activity observed in vitro 
can be translated into inhibition of adhesion molecule expression and a decrease in neutrophil 
infiltration in the arterial wall by reconstituted HDL (rHDL) in a rabbit model of acute arterial 
inflammation (46). The ability of HDL to inhibit adhesion molecule expression may be related to 
the presence of apoA-I, apoA-II, apoA-IV, and/or distinct molecular species of PL, including 
sphingosine-1-phosphate (S1P) and sphingosylphosphorylcholine . The anti-inflammatory action of 
HDL involves inhibition of TNF-α-stimulated activation of sphingosine kinase (47). In addition, 
HDL attenuate IL-6 production in endothelial cells exposed to proinflammatory stimuli, such as 
TNF-α or endotoxin (48).  
The anti-inflammatory action of HDL also involves hydrolysis of oxidized lipids by HDL-
associated enzymes (PAF-AH and PON1) and is mechanistically similar to the antioxidative 
activity of HDL (36,49). Oxidized PL possess potent proinflammatory activities and can trigger 
arterial inflammation. Inactivation of oxidized lipids by HDL may be associated with decreased 
expression of adhesion molecules  and decreased macrophage adhesion to endothelial cells (29).  
Direct interaction of apoA-I with T lymphocytes, which can block subsequent activation of 
monocytes by lymphocytes, represents another plausible mechanism of HDL anti-inflammatory 
action . In addition, apoA-I has been reported to diminish neutrophil activation in vitro. The 
potential heterogeneity of HDL anti-inflammatory activity remains poorly characterized. HDL3 has 
been reported to be superior to HDL2 in terms of its capacity to inhibit vascular cell adhesion 
molecule-1 expression in endothelial cells (17).  
 
4.3.4  Antiapoptotic, Vasodilatory, Antithrombotic, and Anti-Infectious Activities 
 
Other antiatherogenic activities of HDL include antiapoptotic and vasodilatory actions, mitogenic 
activity in endothelial cells, attenuated platelet activation, and anticoagulant and anti-infectious 
activitie.  
HDL potently inhibit apoptosis in endothelial cells induced by oxLDL  or TNF-α ; this effect is 
paralleled by decreased intracellular generation of ROS and diminished levels of apoptotic markers, 
suggesting that it can be related to the intracellular antioxidative actions of HDL or HDL 
components. Indeed, HDL contain bioactive lysophospholipids, including S1P, a potent 
antiapoptotic agent, which may mediate the antiapoptotic effect of HDL via increased NO 
production.   Similarly, HDL vasodilatory activity may be related to the stimulation of NO release 
by endothelial cells mediated by intracellular Ca2+ mobilization and phosphorylation of NOS upon 
association with apoA-I (47). Such activation of NO production involves HDL binding to SR-BI 
with a subsequent increase in intracellular ceramide levels (8). Furthermore, HDL can stimulate 
production of prostacyclin, which possesses potent vasorelaxing activity. S1P may be equally 
important for mitogenic effects of HDL in endothelial cells and for the inhibitory action of HDL on 
the migration of vascular smooth muscle cells (49).  
Similarly, increased production of NO may form a basis for the inhibitory action of HDL on platelet 
aggregation . The antithrombotic activity of HDL is observed as inhibitory actions on factors that 
promote blood coagulation (47). Mechanistically, this effect may be related to the presence of 
cardiolipin and phosphatidylethanolamine, two minor anionic PL with potent anticoagulant 
properties that are enriched in the HDL fraction  (50). In addition, HDL acts via its protein moiety 
to enhance the anticoagulant activity of protein S and activated protein C (47). 
Finally, HDL play a major role in the binding and clearance of circulating endotoxin to the bile and 
thereby inhibit endotoxin-induced cellular activation, resulting in potent anti-infectious activity 
(51). 
The potential heterogeneity of these antiatherogenic activities among HDL particles is 
indeterminate.  
 
 
4.4 Functionally Defective High-Density Lipoprotein in Dyslipidemic and Inflammatory 
States 
 
HDL is known to undergo dramatic modification in structure and composition as a result of the 
concerted actions of the acute-phase response and inflammation. The close association between 
inflammation, oxidative stress, dyslipidemia, and atherosclerosis suggests that such HDL alterations 
play a significant role in disease progression. As a result, HDL particles progressively lose normal 
biological activities and acquire altered properties. Such altered HDL particles have been termed 
“dysfunctional HDL”, and HDL has been proposed to possess “chameleon-like properties. It is 
essential to emphasize that the degree of loss of normal HDL function compared with the absence 
of this function depends on the assay used to characterize HDL functionality (38).  
 
 
4.4.1Altered High-Density Lipoprotein Composition and Enzymatic Activities in Dyslipidemic 
and Inflammatory States 
 
4.4.1.1 Apolipoproteins 
 
Both the plasma levels and apolipoprotein content of HDL can be significantly altered during the 
acute phase as well as during acute and chronic inflammation. Levels of apoA-I and apoA-II 
decrease, whereas those of apoA-IV, apoA-V, apoJ, and apoE increase. The decrease in HDL apoA-
I levels in inflammatory states is related to both decreased apoA-I synthesis in the liver and apoA-I 
replacement in HDL particles by SAA (Fig.2 ). In the circulation, SAA does not exist in a free form, 
it is usually associated with HDL. Elevated plasma levels of SAA are accompanied by elevated 
levels of lipid-free apoA-I, probably due to the dissociation of apoA-I from HDL (52,53). 
 
 
 
Fig. 2.  
Abnormal metabolism and deficient biological activities of HDL in atherogenic dyslipidemias of metabolic disease. Chronic inflammation 
characteristic of metabolic disease, such as MetS and type 2 diabetes, is associated with elevated plasma levels of IL-6. As a result, the liver produces 
SAA, which replaces apoA-I and PON1 in HDL. Oxidative stress, hyperglycemia, and elevated activity of CETP are other important modulators of 
HDL function. Oxidative stress modifies specific amino acids in apoA-I, whereas hyperglycemia results in apoA-I glycation. CETP exchanges CE 
and TG between HDL and TG-rich lipoproteins, such as VLDL; as a result, HDL become enriched in TG. Such enrichment in TG induces 
conformational changes in apoA-I, which becomes less accessible for the interaction with other lipoproteins, including LDL, and cannot eliminate 
oxidized lipids from LDL. Subsequent HDL hydrolysis by HL produces small, dense HDL that are enriched in TG and in SAA and contain apoA-I in 
an incorrect conformation; such HDL possess deficient functionality compared with normal HDL particles.  
 
Apart from its replacement by SAA, apoA-I can undergo other modifications in the circulation. 
Amino acid residues in apoA-I, such as methionine, cysteine, tyrosine, and lysine residues, can be 
selectively modified under the action of prooxidants secreted by arterial wall cells and 
nonenzymatically glycosylated in the presence of high levels of glucose (34). Oxidized amino acid 
residues, including chlorotyrosines, nitrotyrosines and oxidized lysine and methionine residues, are 
present in apoA-I isolated from plasma and from human atherosclerotic lesions ; furthermore, the 
apoA-I content of chloro- and nitrotyrosines is increased in plasma of patients with CV disease.  
Myeloperoxidase was recently shown to bind to HDL within human atherosclerotic lesions, and 
biophysical studies reveal MPO binding occurs via specific interactions with apolipoprotein (apo) 
A-I. This likely facilitates the observed selective targeting of apoA-I for site-specific chlorination 
and nitration by MPO-generated reactive oxidants in vivo. One apparent consequence of MPO-
catalyzed apoA-I oxidation includes the functional impairment of the ability of HDL to promote 
cellular cholesterol efflux via the ABCA1 system. Myeloperoxidase-mediated loss of the 
atheroprotective functional properties of HDL may thus provide a novel mechanism linking 
inflammation andoxidative stress to the pathogenesis of atherosclerosis (54). 
 
 
4.4.1.2 Enzymes with Antioxidative and Anti-Inflammatory Properties 
 
HDL-associated enzymes, including PAF-AH, PON1, and LCAT, can become dysfunctional and/or 
depleted under inflammatory conditions, in metabolic diseases involving low HDL levels (type 2 
diabetes, MetS), and in premature CHD.  HDL provides an amphipathic environment, where PON1 
finds an optimal location to exert its activity. The complex HDL-PON1 is a responsitory for 
potentially toxic, hydrophobic components of plasma, notably oxidized lipids. Induction of the 
acute-phase response is associated with decreased PON1 activity, probably due to the replacement 
of PON1 by SAA (Fig.2 ) (29;36) . Furthermore, decreased PON1 activity may be caused by 
enzyme inactivation as a result of oxidation (55) and/or homocysteinylation and/or     glycation 
(46,64). Consistent with these observations, serum concentrations of PON1 are decreased in 
subjects with MetS (57) and in patients with type 1 and type 2 diabetes, who feature elevated levels 
of inflammation and oxidative stress. Serum PON1 activity decreases with age and is lower in 
subjects with MetS and low HDL-C and patients with type 2 diabetes and familial 
hypercholesterolemia (FH) compared with age-matched healthy control subjects. Moreover, low 
PON1 activity toward paraoxon has been reported to represent an independent risk factor for 
coronary events in men at high CV risk (57,58,59,60).  
HDL-associated PAF-AH activity, expressed as a percentage of total serum PAF-AH activity, is 
lower in hypercholesterolemic  patients than in control subjects. By contrast, LDL-associated PAF-
AH activity is elevated, indicating a major redistribution of PAF-AH activity in plasma of 
dislipidemic individuals from apoA-I- to apoB-containing lipoproteins (61). Finally, LCAT activity 
is diminished under inflammatory conditions (38).  
 4.4.1.3 Lipid Components 
 
Although apolipoproteins and enzymes are major determinants of altered HDL function, it is 
considerably influenced by changes in lipid content. HDL core enrichment in TG with CE depletion 
is the most frequent abnormality of HDL lipid composition (fig.2) and occurs in 
hypertriglyceridemic states, associated with decreased activity of LPL, decreased activity of HL, 
and/or decreased activity of LCAT.  All these metabolic alterations are frequently observed in the 
acute phase and during inflammation (obesity is characterized by a low grade inflammation). In 
addition, HDL-TG content can be raised as a consequence of elevated CETP-mediated TG transfer 
from VLDL to HDL.  Under such conditions, TG typically replace CE in the HDL core, resulting in 
a low CE/TG ratio and in a decrease in plasma HDL-C levels; another feature of the acute phase 
response (62). Interestingly, a similar elevation in HDL-TG, decrease in HDL-C and increase in 
inflammatory markers are observed in the postprandial phase. Human acute-phase HDL obtained 
from patients undergoing bypass surgery are enriched in TG and depleted of CE. Acute-phase HDL 
also contain elevated levels of nonesterified fatty acids (NEFA), lysophosphatidylcholines and 
isoprostanes compared with normal HDL; in addition, CE levels are decreased. Similarly, HDL3 
from subjects with myocardial infarction are enriched in TG and depleted of PL. As a consequence 
of decreased LCAT activity, increased HDL concentrations of free cholesterol are frequently 
observed in inflammatory states; in addition, HDL free cholesterol is elevated in genetic LCAT 
deficiency (62).  
 
 
 
4.5 Abnormal High-Density Lipoprotein Metabolism in Dyslipidemic and Inflammatory 
States 
 
HDL metabolism is substantially altered in dyslipidemic states, including hypertriglyceridemia, 
hypercholesterolemia, mixed dyslipidemia and hypo- and hyperalphalipoproteinemia and also 
during infection and inflammation. As discussed above, hypertriglyceridemia is characterized by 
decreased levels of HDL-C and increased HDL-TG content due to the action of CETP. Such low 
HDL-C dyslipidemias associated with hypertriglyceridemia are characteristic of metabolic diseases 
associated with elevated CV risk, such as type 2 diabetes and MetS. Mechanisms leading to reduced 
plasma HDL-C levels and HDL particle numbers in hypertriglyceridemic states are as follows:  
1) small HDL particles, which result from the intravascular lipolysis of TG-enriched HDL, are 
cleared more rapidly from the circulation;  
2) TG-enriched HDL are intrinsically more unstable in the circulation, with apoA-I loosely bound; 
3) lipolysis of TG-enriched HDL lower HDL particle numbers by causing apoA-I to be shed from 
HDL particles and cleared from the circulation;  
4) dysfunctional LPL or reduced LPL activity contributes to the lowering of HDL levels by 
reducing the availability of surface constituents of TG-rich lipoproteins that sequester to the plasma 
pool of nascent HDL particles (63).  
The CE/TG ratio therefore represents a critical factor in determining HDL particle stability and 
plasma residence time; HDL possessing decreased CE/TG ratios are less stable than normal 
particles (64). Importantly, a decrease in circulating HDL-C levels and an increase in TG levels are 
typical components of the acute-phase reaction (52). HDL metabolism critically depends on the 
activity of CETP. In metabolic diseases such as type 2 diabetes and MetS, elevated CETP activity 
results in increased CE transfer from HDL to TG-rich lipoproteins and in reciprocal TG transfer, 
producing TG-enriched HDL and decreasing HDL-C levels (fig.2). Conversely, CETP deficiency 
reduces the exchange of TG and CE between HDL and TG-rich lipoproteins and elevates HDL-C 
due to CE retention. As a consequence, increased CETP activity is thought to be proatherogenic in 
humans (65). 
In hypercholesterolemia, abnormalities of HDL metabolism include moderate decreases in plasma 
apoA-I and HDL-C levels. HDL heterogeneity and particle profile largely reflect abnormalities in 
HDL metabolism. In the atherogenic dyslipidemias of MetS and type 2 diabetes, circulating levels 
of large, cholesterol-rich HDL decrease in parallel with decrease in HDL-C. By contrast, levels of 
small, dense, cholesterol-poor HDL particles and their content of apoA-I are rarely reduced in low 
HDL-C dyslipidemia (18). In obesity and insulin resistance, frequent features of both MetS and type 
2 diabetes, plasma levels of large HDL decrease in parallel with those of HDL-C, whereas levels of 
small HDL do not. As a result, MetS, type 2 diabetes, obesity, and insulin resistance are all 
characterized by the prevalence of small, dense HDL  (66).  
Small, dense HDL also prevail in CHD patients. In male participants in the Framingham Offspring 
Study, subjects with CHD displayed higher levels of small particles. Similarly, subjects with new 
CV events possessed higher levels of small -HDL and lower levels of large HDL than subjects 
without such events in the Veterans Affairs HDL Intervention Trial (VA-HIT) study (35). CAD 
patients also display elevated levels of lipid-poor apoA-I . The increase in small HDL and decrease 
in HDL of intermediate size as measured by nuclear magnetic resonance are associated with CAD 
severity in men admitted for diagnostic coronary arteriography. Small HDL also prevail in 
peripheral arterial disease (67).  
 
4.6 Impaired High-Density Lipoprotein Biological Activities in Dyslipidemic and 
Inflammatory States 
 
4.6.1 Cholesterol Efflux Capacity 
 
Alterations in HDL composition and metabolism as occur in dyslipidemia and inflammation are 
intimately associated with impaired biological activities (Fig.2). However, data on HDL cholesterol 
efflux capacity in atherogenic dyslipidemia are conflicting. Some authors reported a diminished 
HDL capacity to deliver CE to hepatic cells through interaction with SR-BI as a result of HDL 
enrichment in TG (68).  
By contrast, others have reported normal cholesterol efflux capacity of serum from 
hypertriglyceridemic subjects in Fu5AH cells, an observation that can be related to normal contents 
of HDL-PL, a key determinant of HDL-mediated efflux. Furthermore, HDL from 
hypertriglyceridemic CAD patients with low HDL-C levels possess a normal capacity to extract 
cholesterol from smooth muscle cells . Consistent with these results, TG-enriched HDL are not 
deficient in cholesterol efflux properties from cholesterol-loaded J774 macrophages (69).  
The intrinsic cholesterol efflux capacity of HDL is considerably impaired during inflammation. 
Cellular cholesterol efflux is largely mediated by apoA-I-containing HDL particles; apoA-I 
replacement by SAA can therefore have a significant impact on efflux. Enrichment of HDL with 
SAA (up to high SAA contents of 86% of total HDL protein) results in increased HDL binding to, 
decreased cholesterol efflux capacity from, and increased selective CE uptake by macrophages 
Importantly, SAA selectively impairs cholesterol efflux properties of small, dense HDL3 particles. 
Less pronounced enrichment of HDL with SAA in vivo (up to 27% of total HDL protein) does not 
influence cholesterol efflux but enhances HDL binding to macrophages (70).  
The presence of SAA increases both HDL affinity to and selective CE uptake by macrophages but 
reduces affinity to and CE uptake by hepatocytes. Decreased PL contents in inflammatory HDL 
constitute another factor that contributes to deficient HDL cholesterol efflux properties.Together, 
these changes lead to a significant shift in the HDL-mediated cholesterol transport from hepatocytes 
toward macrophages under acute-phase conditions. Biologically, such alterations may serve to 
redirect cholesterol to immune cells and to sites of injury and inflammation (71).  
Abnormal lipid composition may also impair cholesterol efflux properties of HDL particles, as 
demonstrated by the diminished capacity of large, CE-enriched HDL2 isolated from subjects with 
homozygous CETP deficiency to accept cholesterol from lipid-loaded mouse peritoneal 
macrophages. Normalization of the lipid composition of such HDL, as a result of the transfer of 
excess CE to SR-BI-overexpressing cells, improves HDL cholesterol efflux capacity (71).  
Oxidative modification represents another factor involved in the impairment of HDL cholesterol 
efflux capacity. In vitro oxidation of apoA-I by myeloperoxidase results in selective inhibition of 
ABCA1-dependent cholesterol efflux from macrophages (72). The cholesterol efflux capacity of 
apoA-I may be also impaired as a consequence of nonenzymatic glycosylation (56).  
The central role of apoA-I in HDL-mediated cholesterol efflux is consistent with the deleterious 
role of apoA-I mutations. However, not all mutations in apoA-I lead to decreased cholesterol efflux 
capacity. ApoA-I Milano, a molecular variant of apoA-I, displays potent capacity for cholesterol 
efflux. Carriers of apoA-I Milano exhibit severe hypoalphalipoproteinemia but are not at increased 
risk for premature CHD (73).  
Finally, the capacity of HDL particles to extract cholesterol from peripheral cells may be impaired 
as a result of alterations in cellular HDL receptors, primarily ABCA1 (74).  
 
 
4.6.2 Antioxidative Activity 
 
Recent evidence indicates that HDL particles are deficient in antioxidative activity in atherogenic 
dyslipidemias involving low HDL-C levels (25). Thus, the antioxidative activity of small, dense 
HDL subfractions against LDL oxidation induced by 2,2′-azobis-(2-amidinopropane) hydrochloride 
is significantly impaired in patients with MetS (up to -23%)  and type 2 diabetes (up to -47%) . The 
impaired antioxidative activity of small, dense HDL in MetS and type 2 diabetes is intimately 
related to the concomitant presentation of hypertriglyceridemia, hyperinsulinemia, and insulin 
resistance, thereby suggesting that abnormalities in both lipid and glucose metabolism underlie the 
antioxidative deficiency of HDL particles (75). Furthermore, all HDL subfractions from subjects 
with a normotriglyceridemic, normocholesterolemic, normoglycemic low HDL-C phenotype 
display lower antioxidative activity (up to -43%) than their counterparts from normolipidemic 
control subjects. Interestingly, the intrinsic antioxidative activity of HDL particles is equally 
reduced in subjects with hyperalphalipoproteinemia associated with low HL activity and high HDL-
TG content (76).  
The antioxidative HDL deficiency in low HDL-C dyslipidemias of MetS and type 2 diabetes and in 
a normotriglyceridemic low HDL-C phenotype is paralleled by decreased enzymatic activities and 
altered physicochemical properties of HDL , thereby suggesting that the intrinsic properties of HDL 
particles, rather than low HDL-C levels per se, are determinants of antioxidative deficiency. In each 
study population (MetS, type 2 diabetes, and normotriglyceridemic low HDL-C phenotype), HDL  
particles enrichment in TG and CE depleted, potentially reflect elevated CETP activity and/or 
reduced HL activity; these alterations correlated with the diminished antioxidative activity (75,76). 
Mechanistically, the relationship between TG enrichment of HDL particles and impairment of 
antioxidative activity can be explained by the fact that the replacement of CE by TG in the HDL 
lipid core considerably alters the conformation of the central and C-terminal domains of apoA-I, 
which are critical for HDL to act as an acceptor of oxidized lipids. Moreover, replacement of CE by 
TG in spherical HDL decreases the conformational stability of apoA-I, resulting in TG-containing 
particles, which are unstable and which lose apoA-I upon storage (77).  
Replacement of apoA-I by acute-phase proteins, primarily SAA, in small, dense HDL particles 
under conditions of chronic inflammation  may represent another mechanism contributing to the 
impairment of HDL antioxidative activity. As in the case of the replacement of CE by TG, the 
replacement of apoA-I by SAA may cause deficient activity of HDL as an acceptor of oxidized PL, 
resulting in their elevated accumulation in LDL (36).  
Altered enzymatic activities also contribute to the antioxidative deficiency of small, dense HDL. 
PAF-AH and PON1 activities are consistently lower in all HDL subfractions from patients with 
type 2 diabetes compared with matched normolipidemic control subjects . Moreover, PAF-AH and 
PON1 activities positively correlate withHDL antioxidative activity,suggesting that these enzymes 
are implicated in the deficiency of HDL anti-oxidative function (75). In type 1 diabetes, serum 
concentrations of PON1 are reduced to such an extent that diminished oxidative protection of LDL 
by HDL in vitro results (58). Consistent with this mechanism, inactivation of HDL-associated 
enzymes, such as PON1 or LCAT, by oxidation and/or glycation leads to decreased capacity of 
HDL to protect LDL from oxidative stress (56). The role of enzymes in HDL antioxidative 
deficiency is also consistent with data obtained in obese leptin-deficient (ob/ob), LDL-R-/- mice .  
An antioxidative deficiency of HDL may also be observed when antioxidative activity is measured 
in total HDL, rather than in individual HDL subfractions. Total HDL from humans and rabbits lose 
the ability to protect LDL against oxidation by artery wall cells in coculture during induction of the 
acute phase, concomitant with decreases in PON1 and PAF-AH activities (77). Total HDL from 
mice that are genetically predisposed to diet-induced atherosclerosis do not protect LDL against 
oxidation in cocultures of artery wall cells when the mice are fed an atherogenic diet, injected with 
LDL-derived oxidized PL, or infected with influenza A virus. Such loss of antioxidative activity of 
murine HDL is accompanied by decrease in PON1 activity. In addition, antioxidative deficiency of 
total HDL is observed in both apoE-/- and apoA-II transgenic mice (36,37).  
Furthermore, total HDL-mediated protection of LDL from oxidation by Cu2+ is compromised in 
postmenopausal compared with premenopausal women. This effect is paralleled by decreased 
plasma levels of HDL-C, elevated HDL levels of TG, and increased HDL oxidability in the 
postmenopausal group; the two latter parameters are significantly correlated (78). By contrast, 
serum PON1 activity did not differ between the groups, lending further support to the hypothesis 
that alterations of HDL core lipid composition are a key determinant of the antioxidative function of 
HDL particles (79).  Finally, a diminished capacity of HDL to remove lipid hydroperoxides from 
erythrocyte membranes and attenuated HDL PON1 activity are features of poorly equilibrated type 
1 diabetes (38).  
Despite the fact that HDL antioxidative deficiency has been extensively documented in atherogenic 
dyslipidemias using in vitro assays, direct evidence for its presence in vivo is still lacking.  
 
 
4.6.3 Anti-Inflammatory Activity 
 
HDL particles, possessing antioxidative activity, within the normal range can prevent formation of 
or inactivate proinflammatory oxidized PL produced during LDL oxidation and are therefore anti-
inflammatory. Such potent anti-inflammatory activity becomes deficient and even transforms into in 
vitro pro-inflammatory action under conditions favoring development of atherosclerosis. In contrast 
with functional HDL, proinflammatory dysfunctional HDL is unable to protect LDL from oxidation 
by arterial wall cells and to prevent monocyte migration induced by oxLDL (29). Total HDL from 
CHD patients with normal or elevated HDL-C levels are proinflammatory in both cell culture and 
cell-free fluorescent assays. Similarly, HDL from mice that are genetically predisposed to diet-
induced atherosclerosis become proinflammatory when the mice are fed an atherogenic diet, 
injected with LDL-derived oxidized PL or infected with influenza A virus (29,36).  
Formation of proinflammatory HDL correlates with decreases in the activities of various HDL-
associated enzymes, such as PON1, PAF-AH, and LCAT, which are replaced by acute-phase 
proteins, such as SAA and ceruloplasmin; indeed, the content of these proteins in HDL increases 
during an inflammatory response.  
Interestingly, HDL PON1 activity is not decreased in CHD patients possessing proinflammatory 
HDL, indicating that factors other than PON1 determine anti-inflammatory HDL dysfunction in 
vitro (80). In this study, plasma TG levels were markedly elevated (+76%) in CHD patients 
compared with control subjects (80), suggesting that concomitant HDL enrichment in TG might 
have significantly contributed to the formation of dysfunctional HDL as proposed elsewhere 
(75,76).  
Intriguingly, all of the alterations in HDL composition that lead to attenuated anti-inflammatory and 
anti-oxidative activities (depletion in CE, apoA-I, PON1, and LCAT and increase in TG and SAA) 
are observed during inflammation and in the acute-phase response (80). The pro-inflammatory and 
prooxidative rearrangement of HDL particles and formation of LDL-derived oxidized PL have been 
hypothesized to form part of an evolutionary conserved mechanism of nonspecific innate immunity 
aimed to protect against infection (37). Such an innate inflammatory response may include 
subnormal levels of HDL-C, increased HDL-TG content, and altered HDL apolipoprotein 
composition, all of which impair cholesterol efflux capacity as well as the antioxidant and anti-
inflammatory activities of HDL particles. These modifications in HDL may be aimed to redirect 
cholesterol from the liver to immune cells, particularly macrophages, during infection. Such a 
response to acute infection or injury can be advantageous in the short term but may become 
maladaptive in the long term. A sustained response that is not able to repair the injury, such as an 
emerging atherosclerotic plaque, which can be considered as a local inflammation , may lead to a 
chronic alteration in plasma lipid levels; such a response may become harmful, accelerating the 
formation of atherosclerotic lesions (81). This mechanism is consistent with a recent hypothesis that 
accelerated development of atherosclerosis in old age is related to increased inflammation and 
concomitant endothelial dysfunction during early life. Within this concept, classic lipid changes 
associated with MetS (low HDL-C and elevated TG levels) are envisioned as a highly conserved 
evolutionary response aimed to repair tissue (81).  
The specific association of the deficient antioxidative activity with small, dense together with the 
direct mechanistic link between anti-inflammatory and antioxidative activities suggests that small, 
dense HDL is a major subset of the total HDL particle population, which is responsible for both 
potent anti-inflammatory activity under normal conditions and for deficient activity under pro-
atherogenic, pro-inflammatory conditions (76,29,75). 
 
 
 
 
 
4.7 Physiological Relevance of Defective High-Density Lipoprotein Function in Dyslipidemia 
and Metabolic Disease 
 
The attenuated atheroprotective properties of HDL in metabolic disease raise the possibility of an 
indirect putative proatherogenic effect of these particles. Indeed, attenuated cholesterol efflux 
capacity of HDL can result in enhanced accumulation of cholesterol in the arterial wall and reduced 
RCT flux. Reduced efficiency of cholesterol flux through the RCT pathway is thought to account 
for the epidemiological link between subnormal HDL-C levels and increased incidence of CV 
disease (29,49,47). Impaired RCT has been shown to lead to accelerated atherosclerosis in subjects 
with Tangier disease and in some cases of LCAT deficiency (77). However, no data are available to 
our knowledge on the direct link between atherogenesis and the cholesterol efflux capacity of HDL 
particles, although infusion of apoA-I Milano/phospholipid complex has been shown to lead to a 
reduction in atheroma volume in patients with acute coronary syndromes, suggestive of plaque 
cholesterol efflux (73).  
A deficiency in the antioxidative and anti-inflammatory properties of HDL may also result in 
accelerated atherosclerosis. The oxidation hypothesis of atherosclerosis postulates that oxidation of 
lipoproteins, primarily LDL, in the arterial wall is a key element in atherogenesis. The validity of 
this statement has been confirmed in innumerable. Its important corollary is that deficient LDL 
protection from oxidation may accelerate atherogenesis. Recent data indicate clearly that 
impairment of the antioxidative activity of small, dense HDL in dyslipidemias involving low HDL-
C levels is intimately associated with elevated oxidative stress, a newly recognized CV risk factor , 
and may therefore contribute to enhanced atherogenesis (82). Indeed, dyslipidemic subjects 
presenting with atherogenic low HDL-C levels (MetS, type 2 diabetes, and a normotriglyceridemic 
low HDL-C phenotype) are characterized by both deficient antioxidative activity of small, dense 
HDL and elevated systemic oxidative stress assessed as plasma levels of 8-isoprostanes, products of 
nonenzymatic oxidation of arachidonic acid (75,82,83). Furthermore, HDL antioxidative activity 
and plasma 8-isoprostanes are negatively correlated. In addition, in subjects with controlled type 2 
diabetes, plasma 8-isoprostanes negatively correlate with HDL-C levels, whereas in subjects with a 
normotriglyceridemic low HDL-C phenotype, plasma 8-isoprostanes positively correlate with an 
elevated ratio of total cholesterol/HDL-C, thereby reflecting an excess of atherogenic nonHDL-C 
relative to antiatherogenic HDL-C levels (75,76). The elevation of plasma 8-isoprostanes in subjects 
with low HDL-C dyslipidemias is consistent with the elevation of F2α-isoprostanes in apoA-I 
deficient mice, emphasizing the link between oxidative stress and HDL deficiency. Mechanistically, 
HDL enrichment in TG may play a role in both elevated oxidative stress and the deficiency in HDL 
antioxidative activity, as suggested by strong association between plasma levels of oxLDL and the 
TG/HDL-C molar ratio in elderly subjects (77).  
The presence of defective HDL can facilitate or even trigger accumulation of LDL-derived 
proinflammatory oxidized PL in vivo, resulting in compromised anti-inflammatory activity (80). 
Functional small, dense HDL particles may in turn provide protection of LDL against oxidative 
stress in the subendothelial space of the arterial wall via removal of oxidized lipids from LDL, with 
inactivation and subsequent transfer to the liver mediated by SR-BI. This mechanism may account, 
at least in part, for the negative results of a large-scale placebo-controlled trials that did not show 
any beneficial effect of low-molecular-weight antioxidants, primarily vitamin E, on the 
development of CV disease. The Nutrition Committee of the American Heart Association Council 
on Nutrition, Physical Activity and Metabolism has recently concluded that “the existing scientific 
database does not justify routine use of antioxidant supplements for the prevention and treatment of 
CV disease”. Moreover, a meta-analysis of performed trials suggests that supplementation with 
vitamin E may even increase all-cause mortality. Some authors interpreted these data to indicate 
that low-molecular-weight antioxidants do not play a key role in the protection of LDL from 
oxidation in vivo; by contrast, small, dense HDL may constitute a central element of such 
protection (79).  
The impaired antioxidative activity of small, dense HDL particles in atherogenic dyslipidemia is 
intimately linked to the presence of a constellation of CV risk factors, including 
hypertriglyceridemia, hyperglycemia, hyperinsulinemia, insulin resistance, and a disequilibrium 
between circulating levels of atherogenic apoB-containing lipoproteins and antiatherogenic HDL in 
favor of the former. All of these factors are independently characterized by their significant 
association with elevated systemic oxidative stress (75,76). Such correlational data strongly suggest 
that HDL particles function as a biosensor of oxidative stress, integrating a wide spectrum of 
prooxidant signals; the integration of such signals is in turn expressed as attenuated HDL 
antioxidative activity. Diagnostic detection of HDL possessing deficient antioxidative activity may 
therefore serve as a novel biomarker to assess elevated CV risk.  
 
 
 
 
 
 
 
 THE AIM OF THE STUDY 
 
The pathological evolution of obesity  to  the development a condition of metabolic syndrome 
enhances the alterations of glucose and lipid metabolism.  According to a molecular point of view, 
the cluster of metabolic consequences, in overweight and complicated  overweight, present a 
condition of elevated oxidative stress and a low grade inflammation. The inflammatory response 
promotes the formation of free radicals and reactive oxygen species and the resultant consumption 
of antioxidant molecules. Similarly oxidative stress stimulates the production of inflammatory 
cytokines while maintaining or even extending the same pathogenic mechanisms. At the level of the 
systemic circulation, reactive oxygen species can induce the peroxidative degradation of 
apoproteins and lipids that constitute the plasma lipoproteins. The aim of the study was to observe 
structural and functional modification of plasma lipoproteins in obese subjects with or without 
metabolic syndrome. We proposed to evaluate the lipoproteins change in composition, activity and 
susceptibility to peroxidation. 
Through the use of appropriate fluorescent probes we investigated the susceptibility to peroxidation 
of the different classes of lipoproteins, differentiating between the lipoproteins core and evelope  
comportment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
5.1 Subjects 
 
The recruitment took place at Istituti Clinici di Perfezionamento, Milano.  
To be included in the study, patients had to have the following characteristics: age between 18 and 
55 years (but not in menopause in women), BMI between 25 and 35, absence of major diseases, 
lack of drug therapies in place able to influence the lipid profile (eg. progestogens, statins, oral 
hypoglycemic agents, treatment with thyroid hormone synthesis), lack of use of antioxidant 
supplements, smoking less than 5 cigarettes per day and consumption of alcohol less than 25 g / 
day. All subjects signed an informed consent for membership in the study. The inclusion criteria are 
summarized in Table 2. 
 
Table 2. Inclusion criteria. 
Criteria 
Female and male 
Aged between 18 and 55 years (women: 55 years if not yet in menopause or pre-menopause) 
BMI between  25 and 35 Kg/m2 
Lack of hypo-glycemic treatments or drugs that alter the lipoprotein metabolism in the last 6 weeks  
Lack of use of antioxidant supplements 
Alcohol consumption less than 25 g/day 
Smoking less than 5 cigarettes 
Absence of hormone treatments (including estrogen-progestin) 
Absence of major diseases (heart failure, liver disease, kidney disease, cancer, etc.). 
Provide  a written informed consent 
 
The recruited subjects underwent a dietary first visit. Family history information was collected for 
overweight and obesity, dyslipidemia, diabetes and cardiovascular disease, and later was conducted 
physiological history, investigating in depth the level of physical activity, the characteristics of the 
hive and urine output, the presence of cigarette smoking or consumption of alcoholic beverages, the 
presence of known allergies to drugs, food or pollen and the characteristics of the menstrual cycle 
or the possible presence of menopause in women, were finally carried the proximate and remote 
medical history, investigating the presence of any major diseases or the presence of ongoing drug 
therapy. The patient was then submitted to a complete physical examination, with measurement of 
blood pressure. 
After the visit, it was conducted an interview on the history food eating habits of the patient. 
Dietary food recall was collected with a recall of 24 h plus a survey of food  frequency 
consumption. 
Then patients recruited were invited to the clinic  the day following the first visit, after an overnight 
fast, and to undergo a venous blood sample (20 ml) collected in heparinized tube. The blood sample 
was sent to the Laboratory of Biochemistry, University of Milan (LITA Vialba). From blood 
samples, plasma was obtained by centrifugation at 1000xg at 4 ° C. The plasma was stored at -80 ° 
C until use. The plasma was analyzed to evaluate the oxidative balance and plasma susceptibility to 
peroxidation of plasma lipoproteins. 
Immediately after blood collection, patients underwent a complete anthropometric measurements: 
weight, height, BMI, waist circumference, hip circumference, calculation of waist to hip ratio, arm 
circumference, wrist circumference, biceps skinfold, triceps skinfold, subscapular skinfold. In 
addition, patients were required to undergo in the days immediately following, a venous blood 
sample to perform some routine blood analysis: CBC formula, total cholesterol, HDL cholesterol, 
triglycerides, blood glucose, insulin, glycated hemoglobin , APOA1, ApoB, creatinine, AST, ALT, 
CRP, serum iron, TSH, uric acid. The complete list of evaluations carried out are summarized in 
Table2. The enrolled patients were divided into two study groups: group A consisting of patients 
with metabolic syndrome according to the criteria of the ATP-third  (Table 3) and group B consists 
of patients without metabolic syndrome. 
 
 
 
 
 
 
 Table 3.   
General medical history (family, physiological, pathological proximate and remote) 
 
Physical examination with measurement of PA 
 
Nutritional anamnesis 
Anthropometric measurements (weight, height, BMI, skinfolds and circumferences) 
 
Routine blood tests (CBC with formula, total cholesterol, HDL cholesterol, triglycerides, 
blood glucose, insulin, glycated hemoglobin, APOA1, ApoB, creatinine, AST, ALT, CRP, 
serum iron, TSH, uric acid) 
 
 
 
5.2 Blood collections and separation 
 
A fasting blood sample was drawn for each subject enrolled in the study. The sample was collected 
in appropriate tubes of 4 mL heparinized (1 ml of sodium heparin / mL of blood) and stored at 4 ° C 
to be transported in our laboratories where it is provided for the separation of plasma. 
Each stage of the separation was carried out keeping the sample at a temperature of about 4 ° C by 
using a bath of water and ice. The tubes were centrifuged at 2500 rpm for 10 minutes at 4 ° C 
(centrifuge model ALC. Pk121R). After the first spin the supernatant (plasma) was collected and 
transferred to another tube.(With a plastic pasteur has been removed the whitish pellets (consisting 
of lymphocytes and platelets) that separates the underlying eritociti. The eritociti underwent two 
cycles of washing with an equal volume of a solution of EDTA / NaCl 1:3 and centrifuge at 3000 
rpm for 10 min at 4 ° C). The plasma was subjected to further centrifugation at 3000 rpm for 10 min 
at 4 ° C before being aliquoted and stored at -80 ° C until use (84). 
 
 
5.3 Kinetics of plasma peroxidation 
 
Plasma peroxidation was induced at 37 °C by adding 120 µL of CuSO4 1 mM to 120 µL of plasma 
flow-volume of 2200 µL with 10 mM PBS pH 8.0. 
The peroxidation kinetics were monitored following the formation of fluorescent adducts 
originating from the reaction of polyfunctional aldehydes (derived from plasma lipid peroxidation) 
with amino groups of plasma proteins and/or phospholipids . The development of fluorescence 
emission was monitored at 430 nm, setting the excitation at 360 nm, every 15 min for 8 hours. 
The kinetics are expressed by a sigmoidal curve that can be divided into an initial latency phase 
followed by a second propagation phase. The kinetic profile of these curves allows the evaluation of 
at least two indices and offers a good description of the process of plasma peroxidation (fig.4). 
These indices are: the maximal rate of oxidation, which can be calculated from the slope of the 
fluorescence curve during the propagation phase, and the lag-time, expressed in minutes and 
calculated from the intersection of the linear regression of the propagation phase tangent with that 
of the lag-phase (84). All the measurements were carried out in a Jasco spectrophotofluorimeter FP-
777 equipped with a cuvette holder. The temperature maintained by a Haake GD3 thermostatic 
circulating bath, was monitored with a Subline PT 100 digital thermometer. Salts were purchased 
from Sigma-Aldrich (Milan, Italy) 
 
 
Figure 4 — Fluorescence-determined kinetics of plasma peroxidation. The kinetic curve individuates three phases: a latency phase, a propagation 
phase, and a termination phase. From the data of fluorescence kinetics of plasmatic peroxidation it is possible to determine the time of latency (lag-
time, expressed in minutes) and the maximal rate of the propagation phase (slope, expressed in arbitrary fluorescence units/min).  
 
 
 
  
5.4 Plasma lipoproteins separation 
 
Lipoproteins were separated according to their density by ultracentrifugation from a sample volume 
of 0.9 mL. The plasma density d = 1.006 g/mL was increased to d = 1.3 g/mL by adding an aliquot 
of salt KBr (Sigma) to facilitate separation. 
Two solutions of KBr at density d = 1.0006 g/mL  and d = 1.21 g/mL were stratifcated on the 
sample and we proceeded with a first centrifuge (Beckman TL100 ultracentrifuge) at 100,000 rpm  
T= 4 ° C (AC = 6 , DEC = 6) for 1 hour. The different fractions of lipoproteins were separated into 
bands clearly visible at  different density: VLDL at the top, the LDL in the middle layer and just 
below the HDL plasma proteins remain in the lower part of the tube. The lipoprotein fractions 
VLDL, layered in a volume of 0.5 mL were removed from the upper layer using a fine tip pasteur 
by trying to minimize the disturbance  on the gradient. We proceeded in taking below the LDL 
equal to a volume of 0.7 ml.  An additional centrifuge was used for HDL . A volume of 1 ml was 
collected  and transferred into another tube, the density adjusted with KBr and after statification  
with a salt solution at the density of 1.21 g / mL, was carried out a further centrifuge at 100,000 rpm 
T = 4 ° C (AC = 6, DEC = 6) for 2 hours. The HDL fraction of lipoproteins, layered in a volume of 
1 ml were removed from the top layer. The three lipoprotein fractions brought to a volume of 1 ml 
with PBS 10 mM NaCl 154 mM pH 7.4 were dialyzed to remove excess salt, overnight against 10 
mM NaCl 154 mM PBS pH 7.4, buffer lipoprotein ratio = 1:100 at 4 ° C. Dialysis tubing size 1 Inf. 
Dia 8/32’’ MWCO 12-14000 Daltons were used (Medicell International Ltd) The next morning, 
lipoproteins were removed by dialysis and stored at -80 ° C.  All fluorescence measurements were 
carried out in a Jasco spectrophotofluorimeter FP-777 equipped with a cuvette holder. The 
temperature maintained by a Haake GD3 thermostatic circulating bath, was monitored with a 
Subline PT 100 digital thermometer (85). Salts were purchased from Merk. 
 
 
5.5 Lipoprotein characterization 
 
The protein concentration of each lipoprotein fraction was determined with the Lowry method (86) 
using bovine serum albumin as standard. Total lipids were extracted from each lipoprotein fraction 
following the Folch procedure (85). The phospholipid content was determined according to Bartlett 
(87); cholesterol was determined using a reagent kit from Scalvo (85). All reagents were purchased 
from Sigma-Adrich (Milan-Italy). 
 
5.6 Labelling of lipoproteins with fluorescenct probes 
 
A lipoprotein separation was carried out from plasma previously incubated for one hour at room 
temperature with fluorescent probes. To labell the hydrophobic core of LDL and HDL, plasma was 
incubated with cholesteryl pyrenyl hexanoate, final concentration of 10 nmol/mL  ( Sigma C-2205 
PM=685; P6CHOL) mixed with egg phosphatidylcholine (1:10 mol:mol) (EPG). Decanoyil 
phosphatidylcholine 5 nmol/ml (Sigma P-7657 PM=850,1; P10PC) was used to probes the 
lipoproteins envelope. The probes were suspended with chloroform methanol 2:1, thens evaporated 
with nitrogen. The probes were dissolved with a phisiological solution and then added to plasma. 
(85). 
 
 
5.7 Lipoprotein peroxidation 
 
The two different pyrene derivatives, pyrene decanoyil phosphatidylcholine (P10PC) and cholesteryl 
pyrenyl hexanoate (P6Chol), were used to follow lipid peroxidation in low and high density 
lipoproteins.  We used the fluorescence decrease of P6Chol to monitor the lipid peroxidation in the 
hydrophobic core of LDL and HDL, and that of the amphipatic probes P10PC, to follow lipid 
peroxidation in the envelope of both lipoproteins. 
Peroxidation of LDL and HDL was induced by incubating lipoproteins (0.1 mg protein/ml) 
suspended in 10 mM Tris-HC1, 154 mM NaC1 (pH 7.4) at 37°C with 2,2'-azobis-2-metil-
propanimidamide (AAPH). The AAPH is a water soluble compound which decomposes at 37 ° C 
generating a continuous flow of free radicals. 
The oxidation of labelled LDL and HDL was monitored by the decrease in the pyrene's 
fluorescence emission intensity at 379 nm (excitation 343 nm) . This decrease was expressed as 
((Fo-Ft)/F o) × 100, where F o represents the fluorescence intensity at zero time of peroxidation and 
F t the residual fluorescence for a given peroxidation time. 
The fluorimetrically determined peroxidation profile of each lipoprotein sample can be divided into 
latency, propagation and steady state phases and allows the evaluation of lag time, expressed in 
minutes, calculated as the intercept of the linear least square regression of the propagation phase 
with that of the latency phase (85). All reagents were purchased from Merk.  
 
 
 
5.8 Paraoxonase  
 
Plasma PON1 activity was assayed using two synthetic substrates: paraoxon (diethyl-p-nitrophenyl 
phosphate) and  phenyl acetate.  
PON1 activity toward paraoxon was determined by measuring spectophotometrically at 405 nm  the 
initial rate of substrate hydrolysis to p-nitrophenol. The absorbance was monitored in an assay 
mixture  containing 10 µl  serum and  10 mM paraoxon-ethyl (Sigma-Aldrich, Mialn, Italy).  in a 
Tris–HCl buffer CaCl2 1 mM (pH 8.0). The measurements were carried out at 37°C  with  
VICTOR3™ multilabel readers PerkinElmer equipped with microplate reader. The blank sample 
containing buffer mixture with plasma was run simultaneously. The enzyme activity was calculated 
from molar extinction coefficient of p-nitrophenol (18,290M-1 cm-1) and was expressed in Uml-1; 
1U of enzyme hydrolyses corresponds to 1 nmol of paraoxon per min. Salts were purchased from 
Merk. 
Enzyme activity toward phenyl acetate (arylesterase activity) was determined by measuring the 
initial rate of substrate hydrolysis in the assay mixture containing 5 ul serum, 10 mM phenyl acetate 
(Sigma-Aldrich, Milan, Italy) in a Tris–HCl buffer CaCl2 1 mM (pH 8.0). The absorbance was 
monitored for 1 min at 270 nm and the activity was calculated from molar extinction coefficient 
(1310 M-1 cm-1). The results are expressed in Uml-1; 1U of arylesterase hydrolyses corresponds to 1 
mol of phenyl acetate per min (88). 
The measurements were carried out at 37°C  with  V-550 Jasco Spectrophotometer. Salts were 
purchased from Merk. 
 
 
5.9 Plasma ROS levels 
 
Plasma ROS levels were measured using a colorimetric kit (d-ROM test; Diacron, Grosseto, Italy); 
the results are expressed as H2O2 equivalents, according to the manufacturer’s instructions (89). 
 
5.10 Statistics 
 
The average values in the SM and OB groups were compared with each other and compared to 
those previously obtained by a group of normal-weight subjects, matched for age and sex. The 
differences between the two groups were analyzed statistically using the Mann-Whitney test and 
were considered significant for p values ≤ 0.05. 
RESULTS AND DISCUSSION 
 
6.1 Patients  
 
To date 98 patients were enrolled of which 70 obese (40 males  and 30 females) and 28 obese (20 
males  and 8 females) with metabolic syndrome. As the number of female subjects with metabolic 
syndrome is currently few in number and gender influence the lipoprotein metabolism, we present 
only the results for males. 
Therefore, the following results refer to the comparison between the group of 40 obese men without 
the syndrome (OB) and  20 obese men with metabolic syndrome (MS) (Tab. 4.). the two groups are 
homogeneous for age and BMI. Significant are the differences in some parameters that characterize 
the metabolic syndrome such as triglycerides and HDL. The waist  circumferences  are not diffent 
in the two groups but there is a significant difference in WHR. WHR expresses the ratio between 
waist circumference and hip circumference. This index is used in the medical field to assess the 
distribution of body fat. No differences  were found in blood glucose levels while insulin and 
HOMA, two parameters involved in glucose metabolism are significative different. The two groups 
differ for PCR,  a protein which increases its blood concentration  in inflammatory processes. 
Arilesterase activity of enzyme  paraoxonase was very similar in both groups, while paraoxon 
activity was reduced by 15% in MS than in OB, but this reduction was not statistically significant. 
 
 
  Tab. 4 
 
OB (n=40) SM (n= 20) p 
 
means SEM means SEM 
 
AGE (YEARS) 44 1.8 48 2.3 ns 
BMI (kg/m2 30.1 0.4 30.9 0.4 ns 
Skinfold  triceps (mm) 21.8 1.1 24.3 1.6 ns 
Skinfold  biceps (mm) 16.3 0.9 15.2 1.3 ns 
Skinfold  subscapolar(mm) 33.9 2.0 35.2 0.9 ns 
WHR 0.97 0.008 1.02 0.05 <0.01 
Waist  circumferences(cm) 105.0 1.2 107.5 0.9 ns 
Triglycerides (mg/dl) 111 9 170 23 <0.05 
Total  Cholesterol (mg/dl) 205 5.7 222 7 ns 
HDL (mg/dl) 52 1.7 42 1.8 <0.01 
DBP (mm Hg) 82 1.5 80 1.4 ns 
SBP(mm Hg) 132 1.8 135 2.6 ns 
gluc (mg/dl) 91 1.3 97 2.9 ns 
Insulin  (µU/ml) 7.0 0.7 13.1 1.1 <0.01 
HOMA 1.5 0.15 3.2 0.3 <0.01 
CRP (mg/dl) 0.17 0.01 0.44 0.06 <0.01 
Paroxon activity(U/ml) 127 13 107 15 ns 
Arilesterase activity (U/ml) 74 2.5 72 3.4 ns 
 
 
 
 
 
 
 
 
 
 
  
 
6.2 Susceptibility to peroxidation and ROS plasma levels 
 
The parameters indicative of the susceptibility to peroxidation (lag-time and slope of the kinetics of 
peroxidation) and ROS plasma levels were significantly worse in the group of obese (OB) and in 
the obese with metabolic syndrome (MS) than in healthy controls CT , but there were no significant 
differences between OB and MS (Tab.5). 
. 
 
Tab.5 
 
CT (n =50) OB (n=40) SM (n= 20 ) 
 
means SEM means SEM means SEM 
Lag-time  
(min) 
167* 2.5 147 3.2 145 4.0 
Slope (% 
decrease/min) 1.05* 0.03 1. 3 
0.06 1.3 0.09 
ROS (mg/dl) 22.4* 07 30.4 0.6 29.6 0.9 
* p< 0.05 vs OB e SM 
 
 
 
 
 
 
 
 
6.3 Lipoproteins composition 
 
Lipoproteins analysis showed statistically significant differences between the two groups in lipid 
composition. HDL and LDL in the MS group had a higher content of triglycerides (tab.6) according 
with data present in literature (62). 
Tab.6 
 
* P < 0.05 OB vs SM 
 
 
 
 
 
 
 
 
 
 
VLDL LDL HDL 
OB 
 (n=40) 
SM 
 (n=20) 
OB 
 (n=40) 
SM 
 (n=20) 
OB 
 (n=40) 
SM 
 (n=20) 
Proteins 
(mg/ml) 258 ±23  327 ±41  930 ± 50 1042 ±64 763 ±38 832 ± 81 
Phospholipids 
(% w/w) 19.5 ± 1.5 15.3± 2.4 34.6 ± 0.8  32.5± 0.8 46.0 ± 2  42.0 ± 3 
Cholesterol 
(% w/w) 29.2 ± 1 30.7 ±0.8 48.9 ± 0.8  47.2 ±1.0  37.3  1.2  39.6 ±2 
Triglycerides 
(% w/w) 51.3 ±1.6 54.0 ±2.7 16.4±0.7* 21.2 ±1.4 16.7 ± 1* 26.1 ± 1 
6.4 HDL  susceptibility to oxidation 
 
The hydrophobic core of HDL in subjects OB has a greater resistance to peroxidation (lag-
time).The other parameters indicative of susceptibility to peroxidation of lipoproteins HDL and 
LDL despite being the best in the group OB, statistically did not differ significantly between the 
two groups (tab.7). 
 
 
Tab. 7 
 
 
 
 
  OB SM  p 
  means SEM means SEM   
Hydrophilic Envelope: 
Lag-time (min) 14.9 0.9 11.3 1 ns 
Slope (% decrease/min) 1.45 0.1 1.65 0.09 ns 
Hydrophobic Core : 
Lag-time (min) 9.6 0.5 4.3 0.8 0.03 
Slope (% decrease/min) 1.26  0.3 1.51 0.05 ns 
CONCLUSION 
 
 
The results of this study revealed that overweight and obesity may increase the risk of peroxidation 
of HDL and LDL.  The metabolic syndrome can further accentuate the degradation processes, 
especially in the hydrophobic  core of HDL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIBLIOGRAPHY 
 
1. Executive summary of the third report of the National Cholesterol Education Program 
(NCEP) export panel on detection evaluation and treatment of high blood cholesterol in 
adults. JAMA 2001; 285: 2486-2497. 
2. Guilherme A et al. Adipocyte dysfunctions linking obesity to insulin  resistence and type 
2 diabetes. NATURE REVIEWS 2008; 9: 367-377. 
3. Hsu R et al. Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 2007; 
86:867s-71s. 
4. Encyclopedia of human nutrition. 
5. Verhoye E et al. Circulating oxidized low-density lipoprotein: a biomarker of 
atherosclerosis and cardiovascular risk? Clin Chem Lab Med 2009; 47(2):128-137. 
6. Chancharme L et al. LDL particles subclasses in hypercholesterolemia.Molecular 
determinants of reduced lipid hydroperoxide stability. J lipid res 2002;43:453-62. 
7. Steinberg D. et al. Low density lipoprotein oxidation and its pathobiological 
significance. J biol chem 1997;272:20963-6. 
8. Holvoet P et al. Oxidized LDL and malondialdehyde-modified LDL in patients with 
acute coronary syndromes and stable coronary arthery disease,Circulation 1998;98:1487-
94. 
9. Berliner JA et al. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol 
Med 1996; 20: 707-27. 
10. Gordon DJ et al. High density lipoprotein – the clinical implications of recent studies. N 
Engl J Med 1989;321: 1311-6. 
11. Wilson PW et al. High density lipoprotein cholesterol and mortality. The Framingham 
Heart Study. Arteriosclerosis 1988;8:737-41. 
12. Asztalos BF et al. HDL in atherosclerosis: actor or bystander? Atheroscler Suppl 2003;4: 
21-29. 
13. Barter PJ  et al. Cholesteryl ester transfer protein: a novel target for raising HDL and 
inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 160-167. 
14. Segrest JP et al. A detailed molecular belt model for apolipoprotein A-I in discoidal high 
density lipoprotein. J Biol Chem 1999;274: 31755-31758. 
15. Segrest JP et al. Detailed molecular model of apolipoprotein A-I on the surface of high-
density lipoproteins and its functional implications. Trends Cardiovasc Med  2000;10: 
246-252. 
16. Silva RA et al. A mass spectrometric determination of the conformation of dimeric 
apolipoprotein A-I in discoidal high density lipoproteins. Biochemistry 2005; 44: 8600-
8607. 
17. Kontush A et al. Small, dense HDL particles exert potent protection of atherogenic LDL 
against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23: 1881-1888. 
18. Kontush A et al. Antioxidative activity of HDL particle subspecies is impaired in 
hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties. 
Arterioscler Thromb Vasc Biol 2004; 24: 526-533. 
19. Maiorano JN et al. Identification and structural ramifications of a hinge domain in 
apolipoprotein A-I discoidal high-density lipoproteins of different size. Biochemistry  
2004;43: 11717-11726. 
20. Chapman MJ et al. Raising high-density lipoprotein cholesterol with reduction of 
cardiovascular risk: the role of nicotinic acid—a position paper developed by the 
European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20: 1253-1268. 
21. Rosenson RS et al. Relations of lipoprotein subclass levels and low-density lipoprotein 
size to progression of coronary artery disease in the Pravastatin Limitation of 
Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002;90: 89-94. 
22. Mackey RH et al. Lipoprotein subclasses and coronary artery calcium in postmenopausal 
women from the healthy women study. Am J Cardiol 2002;90: 71i-76i. 
23. Rye KA et al. Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein 
A-I. Arterioscler Thromb Vasc Biol 2004;24: 421-428. 
24. Atmeh RF et al. Small high density lipoprotein subclasses: some of their physico-
chemical properties and stability in solution. Acta Biochim Pol 2005;52: 515-525. 
25. Oram JF The cholesterol mobilizing transporter ABCA1 as a new therapeutic target for 
cardiovascular disease. Trends Cardiovasc Med 2002;12: 170-175. 
26. Von Eckardstein A et al. High density lipoproteins and arteriosclerosis: role of 
cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 
2001;21: 13-27. 
27. Santamarina-Fojo S et al. Hepatic lipase, lipoprotein metabolism, and atherogenesis. 
Arterioscler Thromb Vasc Biol 2001;24: 1750-1754. 
28. Clay MA et al. Cholesteryl ester transfer protein and hepatic lipase activity promote 
shedding of apo A-I from HDL and subsequent formation of discoidal HDL. Biochim 
Biophys Acta 1992;1124: 52-58. 
29. Navab M et al. The oxidation hypothesis of atherogenesis: the role of oxidized 
phospholipids and HDL. J Lipid Res 2004;45: 993-1007. 
30. Langmann T et al. Molecular cloning of the human ATP-binding cassette transporter 1 
(hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys 
Res Commun 1999;257: 29-33. 
31. Oram JF et al. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates 
cholesterol secretion from macrophages. J Biol Chem 2000;275: 34508-34511. 
32. Kennedy MA et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL 
and preventing cellular lipid accumulation. Cell Metab 2005;1: 121-131. 
33. Yancey PG et al. SR-BI- and ABCA1-mediated cholesterol efflux to serum from patients 
with Alagille syndrome. J Lipid Res 2004;45: 1724-1732. 
34. Mazzone T Apolipoprotein E secretion by macrophages: its potential physiological 
functions. Curr Opin Lipidol 1996;7: 303-307. 
35. Asztalos BF et al. Differential effects of HDL subpopulations on cellular ABCA1- and 
SR-BI-mediated cholesterol efflux. J Lipid Res 2005;46: 2246-2253. 
36. Van Lenten BJ et al. The role of high-density lipoproteins in oxidation and 
inflammation. Trends Cardiovasc Med 2001;11: 155-161. 
37. Navab M et al. Normal high density lipoprotein inhibits three steps in the formation of 
mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000;41: 1495-1508. 
38. Ferretti G et al. Structural modifications of HDL and functional consequences. 
Atherosclerosis 2005;184: 1-7. 
39. Bowry VW et al. High density lipoprotein is the major carrier of lipid hydroperoxides in 
human blood plasma from fasting donors. Proc. Natl. Acad. Sci. U.S.A. 1992;89: 10316-
10320. 
40. Raffai RL et al. Apolipoprotein E promotes the regression of atherosclerosis 
independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol 
2005;25: 436-441. 
41. Ribas V et al. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL 
and impairs its antioxidant properties: a new mechanism linking HDL protein 
composition and antiatherogenic potential. Circ Res 2004;95: 789-797. 
42. Aviram M et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves 
its functions: a possible peroxidative role for paraoxonase. J Clin Investig 1998;101: 
1581-1590. 
43. James RW et al. The importance of high-density lipoproteins for paraoxonase-1 
secretion, stability, and activity. Free Radic Biol Med 2004;37: 1986-1994. 
44. Arakawa H et al. Local expression of platelet-activating factor-acetylhydrolase reduces 
accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced 
thrombosis, and neointima formation in balloon-injured carotid arteries in 
nonhyperlipidemic rabbits. Circulation 2005;111: 3302-3309. 
45. Rosenblat M et al. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage 
cholesterol efflux via the ABCA1 transporter in association with increased HDL binding 
to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 2005;179: 69-
77. 
46. Nicholls SJ et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant 
and proinflammatory vascular changes induced by a periarterial collar in 
normocholesterolemic rabbits. Circulation 2005;111: 1543-1550. 
47. Nofer JR et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. 
Atherosclerosis 2002;161: 1-16. 
48. Gomaraschi M et al. High-density lipoproteins attenuate interleukin-6 production in 
endothelial cells exposed to pro-inflammatory stimuli. Biochim Biophys Acta 
2005;1736: 136-143. 
49. Nofer J-R et al. Atheroprotective effects of high-density lipoprotein-associated 
lysosphingolipids. Trends Cardiovasc Med 2005;15: 265-271. 
50. Deguchi H et al. Cardiolipin is a normal component of human plasma lipoproteins. Proc 
Natl Acad Sci USA 2000;97: 1743-1748. 
51. Stoll L et al. Potential role of endotoxin as a proinflammatory mediator of 
atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24: 2227-2236. 
52. Khovidhunkit W et al. Effects of infection and inflammation on lipid and lipoprotein 
metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45: 1169-1196. 
53. Esteve E et al. Dyslipidemia and inflammation: an evolutionary conserved mechanism. 
Clin Nutr 2005;24: 16-31. 
54. Stephen J et al. Formation of Dysfunctional High-Density Lipoprotein by 
Myeloperoxidase.  Trends in Cardiovascular Medicine  2005;15(6):212-219. 
55. Jaouad L et al. PON1 paraoxonase activity is reduced during HDL oxidation and is an 
indicator of HDL antioxidant capacity. Free Radic Res 2003;37: 77-83 
56. Ferretti G  et al. Structural modifications of HDL and functional consequences. 
Atherosclerosis. 2006;184(1):1-7. 
57. Blatter Garin MC et al. Small, dense lipoprotein particles and reduced paraoxonase-1 in 
patients with the metabolic syndrome. J Clin Endocrinol Metab 2005;90: 2264-2269. 
58. Boemi M et al. Serum paraoxonase is reduced in type 1 diabetic patients compared to 
non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from 
oxidation. Atherosclerosis 2001;155: 229-235. 
59. Costa LG et al. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 
2005;69: 541-550. 
60. Mackness MI et al. Serum paraoxonase activity in familial hypercholesterolaemia and 
insulin-dependent diabetes mellitus. Atherosclerosis 1991;86: 193-199. 
61. Tsimihodimos V et al. Altered distribution of platelet-activating factor-acetylhydrolase 
activity between LDL and HDL as a function of the severity of hypercholesterolemia. J 
Lipid Res 2002;43: 256-263. 
62. Pruzanski W et al. Comparative analysis of lipid composition of normal and acute-phase 
high density lipoproteins. J Lipid Res 2000;41: 1035-1047. 
63. Lamarche B et al. HDL metabolism in hypertriglyceridemic states: an overview. Clin 
Chim Acta 1999;286: 145-161. 
64. Rashid S et al. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic 
states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase 
activity. Clin Biochem 2003;36: 421-429. 
65. Barter PJ et al. Cholesteryl ester transfer protein: a novel target for raising HDL and 
inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23: 160-167. 
66. Garvey WT et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass 
particle size and concentration determined by nuclear magnetic resonance. Diabetes 
2003;52: 453-462. 
67. Suzuki M et al. Increased plasma lipid-poor apolipoprotein A-I in patients with coronary 
artery disease. Clin Chem 2005;51: 132-137. 
68. Palmer AM et al. Triglyceride-rich lipoproteins inhibit cholesterol efflux to 
apolipoprotein (apo) A1 from human macrophage foam cells. Atherosclerosis 2004;173: 
27-38. 
69. Uint L et al.  Cellular cholesterol efflux mediated by HDL isolated from subjects with 
low HDL levels and coronary artery disease. Arq Bras Cardiol 2003;81: 39-41, 35-38. 
70. Kinoshita M et al. Scavenger receptor type BI potentiates reverse cholesterol transport 
system by removing cholesterol ester from HDL. Atherosclerosis 2004;173: 197-202. 
71. Artl A et al. Impaired capacity of acute-phase high density lipoprotein particles to 
deliver cholesteryl ester to the human HUH-7 hepatoma cell line. Int J Biochem Cell 
Biol 2002;34: 370-381. 
72. Zheng L et al. Localization of nitration and chlorination sites on apolipoprotein A-I 
catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment 
in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 2005;280: 38-
47. 
73. Sirtori CR et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) 
mutant: the Limone sul Garda study. Circulation 2001;103: 1949-1954. 
74. van Dam MJ et al. Association between increased arterial-wall thickness and impairment 
in ABCA1-driven cholesterol efflux: an observational study. Lancet 2002;359: 37-42. 
75. Nobecourt E et al. Defective antioxidative activity of small, dense HDL particles in type 
2 diabetes: relationship to elevated oxidative stress and hyperglycemia. Diabetologia 
2005;48: 529-538 
76. Kontush A et al. A normotriglyceridemic, low HDL-cholesterol phenotype is 
characterised by elevated oxidative stress and HDL particles with attenuated 
antioxidative activity. Atherosclerosis 2005;182: 277-285. 
77. Scanu  AM et al. HDL: bridging past and present with a look at the future  The FASEB 
Journal 2008;22: 4044-4054. 
78. Zago V et al. Impaired high density lipoprotein antioxidant activity in healthy 
postmenopausal women. Atherosclerosis 2004;177: 203-210. 
79. Kontush  A et al. Functionally Defective High-Density Lipoprotein: A New Therapeutic 
Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol 
Rev September 2006 58:342-374. 
80. Ansell BJ et al. Inflammatory/antiinflammatory properties of high-density lipoprotein 
distinguish patients from control subjects better than high-density lipoprotein cholesterol 
levels and are favorably affected by simvastatin treatment. Circulation 2003;108: 2751-
2756. 
81. Esteve E et al. Dyslipidemia and inflammation: an evolutionary conserved mechanism. 
Clin Nutr 2005;24: 16-31. 
82. Vergeer M et al. The HDL hypothesis: does high-density lipoprotein protect from 
atherosclerosis? J  Lipid Res 2010;51:2058-2073. 
83.   Shao B et al. HDL, lipid peroxidation, and atherosclerosis J Lipid Res 2009;50:599-
601.  
84. Cervato G et al. A fluorescence method for the determination of plasma susceptibility to 
lipid peroxidation. Clin Biochem 1999;32(3): 171-7. 
85. P.Viani et al.  Pyrene lipids as markers of peroxidative processes in different regions of 
low and high density lipoproteins. Biochimica and Biophysica Acta 1996;1315: 78 – 86. 
86. Lowry  OH et al. Protein measurement with the Folin phenol reagent J Biol Chem 
1951;193: 265-275. 
87. Bartlett GR et al. Phosphorus assay in column chromatography J Biol Chem 1959;234: 
466-468. 
88. Rosenblat  M et al. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of 
macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient 
serum: relevance to diabetes Atherosclerosis 2006;187(1):74-81. 
89. Cazzola R. et al. Oxidative state and lipid composition of plasma from overweight and 
moderately obese women Mediterr J Nutr Metab 2008; 1:19–24. 
 
 
 
 
 
 
 
 
 
 
 
